诺和锐30联合二甲双胍治疗30例2型糖尿病患者的临床观察

The clinical observations of biphasic insulin aspart 30 in combination with metformin in 30 poorly controlled type 2 diabetes.

目的了解诺和锐30联合二甲双胍治疗对口服降糖药控制不理想的2型糖尿病患者血糖的进一步控制和安全性。方法通过对30例口服降糖药治疗血糖和糖化血红蛋白控制不佳的2型糖尿病患者用诺和锐30联合二甲双胍治疗24周的观察。在治疗0、12、24周分别测体重,BMI,空腹血糖(FPG),三餐后2h血糖(PPG)以及糖化血红蛋白(HbA1c)水平,了解治疗前12周和后12周的低血糖发生情况。结果治疗0周,12周,24周30例患者的体重,BMI无明显变化(P>0.05),治疗12周和24周空腹血糖,三餐后2h血糖以及糖化血红蛋白水平均较治疗前明显降低,差异有统计学意义(P<0.01),治疗12周和24周的空腹血糖,三餐后2h血糖和糖化血红蛋白水平无明显变化(P>0.05),治疗前12周和后12周的低血糖发生率无明显变化(P>0.05)。结论诺和锐30联合二甲双胍治疗对口服降糖药控制不佳的2型糖尿病患者可以进一步降低血糖和糖化血红蛋白,而体重,BMI增加不明显,低血糖发生率低。诺和锐30联合二甲双胍治疗是口服降糖药控制不佳的2型糖尿病患者安全有效的治疗方案。

Objective To investigate the efficacy and satefy of biphasic insulin aspart 30 in combination with metformin to treat diabetic patients whose glucose are poorly controlled with oral antidiabetic drugs（OADs）.Methods 30 type 2 diabetes whose glucose and HbA1c were not controlled well with oral antidiabetic drugs,they were then treated with biphasic insulin aspart 30 and metformin for 24 weeks.Weight,fasting plasma glucose（FPG）,postprandial 2-hour plasma glucose（PPG）and HbA1c were measured at 0 week,12 week and 24 week respectively.Hypoglycemia was also observed.Results No significant differences in weight gain and BMI were observed at 0 week,12 week and 24 week.The levels of FPG,PPG of the three meals and HbA1c were significant lower at 12 week and 24 week compared with 0 week（P〈0.01）.However,The levels of FPG,PPG of the three meals and HbA1c were not significant difference between 12 week and 24 week（P〉0.05）.There were no difference between the first 12 week and the second 12 week in the rate of Hypoglycemia.Conclusion BIAsp 30 in combination with metformin offered greater reduction in FPG,PPG and HbA1c without increasing risk of hypoglycemia and weight gain.The combination of BIAsp 30 and metformin is a good and safe choice in subjects with type 2 diabetes inadequately controlled with oral antidiabetic drugs（OADs）.